
Paolo Tarantino/X
May 27, 2025, 21:32
Paolo Tarantino: PATINA Trial and First-Line Options for HR+/HER2+ MBC
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“PATINA tested maintenance ET/palbo/HER2-block after induction chemo/HER2-block for HR+/HER2+ MBC. mPFS 44 months DB09 may add the option of 1L T-DXd/P used continuously (no induction tested).
If both available, would you adopt the PATINA maintenance after induction T-DXd/P?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 28, 2025, 21:15
May 28, 2025, 20:09